Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05186324 · ClinicalTrials.gov registry record
Fabry Patient's Experience Of PegunigaLsidasE Alfa Monthly Infusion
A clinical trial, sponsored by Chiesi Farmaceutici S.p.A..
- Completed
- Registry status
- 23
- Enrollment target
NCT05186324: Completed study, sponsored by Chiesi Farmaceutici S.p.A..
NCT05186324 is a clinical trial that has completed, run by Chiesi Farmaceutici S.p.A.. The registered enrollment target is 23 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05186324 has completed, sponsored by Chiesi Farmaceutici S.p.A..
- COMPLETED
- Registry status
- 23 participants
- Enrollment target
Study Summary
Pegunigalsidase alfa (PRX-102) is a long-term enzyme replacement therapy design for the treatment of patients with Fabry disease. Although in the clinical development program patient-reported outcomes and clinician-reported outcomes have been included, this may not allow for a sufficiently accurate assessment of the quality of life in patients with Fabry Disease treated with pegunigalsidase alfa. This study will collect the patient experience on the pegunigalsidase alfa treatment administered intravenously every 4 weeks in the BRIGHT-F51 clinical study (NCT03614234).
Primary Outcome
Description of the symptoms experienced by patients treated with pegunigalsidase alfa for more than 2 years
Interventions
- OTHER Interview
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2022-01-26 |
| Est. Completion | 2022-08-31 |
What the finished NCT05186324 record still lists
NCT05186324 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 23 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Interview is the first listed.
NCT05186324 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05186324 about?
NCT05186324 is a clinical study titled "Fabry Patient's Experience Of PegunigaLsidasE Alfa Monthly Infusion". Pegunigalsidase alfa (PRX-102) is a long-term enzyme replacement therapy design for the treatment of patients with Fabry disease. Although in the clinical development program patient-reported outcomes and clinician-reported outcomes have been included, this may not allow for a sufficiently accurate ...
What is the current status of trial NCT05186324?
This trial is currently completed. The enrollment target is 23 participants. The study started on 2022-01-26. Estimated completion is 2022-08-31.
What interventions are being tested in trial NCT05186324?
The interventions under investigation include: Interview (OTHER).
Who is sponsoring clinical trial NCT05186324?
This trial is sponsored by Chiesi Farmaceutici S.p.A., which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI